<DOC>
	<DOC>NCT02179151</DOC>
	<brief_summary>The purpose of this study is to evaluate efficacy and safety of ZGN-440 (beloranib) in obese adolescent and adult subjects with Prader-Willi Syndrome.</brief_summary>
	<brief_title>Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome</brief_title>
	<detailed_description>Phase 3, Randomized, Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Subcutaneous Beloranib in Suspension) in Obese Subjects with Prader-Willi Syndrome to Evaluate Total Body Weight, Food-related Behavior, and Safety Over 6 Months</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Prader-Willi Syndrome</mesh_term>
	<criteria>Confirmed genetic diagnosis of PraderWilli Syndrome Age 1265 Obesity Age 1217: BMI ≥ 95th percentile for age and gender Age 1865: BMI ≥27 to ≤60 kg/m2 Subjects living in a group home ≥ 50% of the time Recent use (within 3 months) of weight loss agents including herbal medication Poorly controlled severe psychiatric disorders</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Prader-Willi Syndrome</keyword>
	<keyword>Obesity</keyword>
	<keyword>Hyperphagia</keyword>
</DOC>